Thomas Woiwode, Director at CRISPR Therapeutics AG (CRSP), sold 1,900 shares at $20.21 ($38K) on 2017-11-24, disclosed to the SEC on 2017-11-28.
Scheduled sale ($38k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.21 | 1,700 | $34K | 89.5% |
| 2 | $20.24 | 200 | $4K | 10.5% |
| Total | $20.21 avg | 1,900 | $38K | 100% |
| Filing → |
| ALGS | BUY | 2020-10-20 | $3.0M | — | Filing → |
| PASG | BUY | 2020-03-03 | $4.0M | — | Filing → |
| CRSP | SELL | 2018-05-17 | $2.6M | — | Filing → |